INDIANAPOLIS (AP) — Eli Lilly and Co.’s fourth quarter earnings slipped 4 percent as generic competition continued to eat away at sales of its former best-seller, the antipsychotic Zyprexa, but the drugmaker cut expenses again and growth from other products helped it beat analyst expectations.
It also raised its forecast for 2013, and its shares edged up in premarket trading.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.